» Articles » PMID: 33414765

L-T4 Therapy in the Presence of Pharmacological Interferents

Overview
Specialty Endocrinology
Date 2021 Jan 8
PMID 33414765
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Pharmacological interference on L-thyroxine (L-T4) therapy can be exerted at several levels, namely from the hypothalamus/pituitary through the intestine, where the absorption of exogenous L-T4 takes place. A number of medications interfere with L-T4 therapy, some of them also being the cause of hypothyroidism. The clinician should be aware that some medications simply affect thyroid function tests with no need of modifying the dose of L-T4 that the patient was taking prior to their prescription. Usually, the topic of pharmacological interference on L-T4 therapy addresses the patient with primary hypothyroidism, in whom periodic measurement of serum thyrotropin (TSH) is the biochemical target. However, this minireview also addresses the patient with central hypothyroidism, in whom the biochemical target is serum free thyroxine (FT4). This minireview also addresses two additional topics. One is the costs associated with frequent monitoring of the biochemical target when L-T4 is taken simultaneously with the interfering drug. The second topic is the issue of metabolic/cardiovascular complications associated with undertreated hypothyroidism.

Citing Articles

Hypothyroidism and metabolic cardiovascular disease.

Patrizio A, Ferrari S, Elia G, Ragusa F, Balestri E, Botrini C Front Endocrinol (Lausanne). 2024; 15:1408684.

PMID: 38887272 PMC: 11180764. DOI: 10.3389/fendo.2024.1408684.


The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum.

Deligiorgi M, Trafalis D J Clin Med. 2022; 11(12).

PMID: 35743483 PMC: 9224934. DOI: 10.3390/jcm11123417.

References
1.
Feldt-Rasmussen U, Klose M . Central hypothyroidism and its role for cardiovascular risk factors in hypopituitary patients. Endocrine. 2016; 54(1):15-23. DOI: 10.1007/s12020-016-1047-x. View

2.
Shah P, Dickler M . Endocrine therapy for advanced breast cancer. Clin Adv Hematol Oncol. 2014; 12(4):214-23. View

3.
Sahajpal R, Ahmed R, Hughes C, Foisy M . Probable interaction between levothyroxine and ritonavir: Case report and literature review. Am J Health Syst Pharm. 2017; 74(8):587-592. DOI: 10.2146/ajhp160200. View

4.
Hamed S . The effect of antiepileptic drugs on thyroid hormonal function: causes and implications. Expert Rev Clin Pharmacol. 2015; 8(6):741-50. DOI: 10.1586/17512433.2015.1091302. View

5.
Figaro M, Clayton Jr W, Usoh C, Brown K, Kassim A, Lakhani V . Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review. Am J Hematol. 2011; 86(6):467-70. DOI: 10.1002/ajh.22008. View